{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:07:54Z","timestamp":1791828474768,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1053\/j.seminoncol.2004.03.035","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"12-17","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S6","title":["Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome"],"prefix":"10.1053","volume":"31","author":[{"given":"Richard M","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.Gary","family":"Gilliland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy D","family":"Klion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.03.035_BIB1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-97-1-78","article-title":"NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations","volume":"97","author":"Fauci","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB2","series-title":"Harrison\u2019s Principles of Internal Medicine","first-page":"351","article-title":"Disorders of granulocytes and monocytes","author":"Holland","year":"1997"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB3","first-page":"218","article-title":"When is the \u201cidiopathic\u201d hypereosinophilic syndrome eosinophilic leukaemia?","volume":"21","author":"Bain","year":"1996","journal-title":"Ned Tijdschr Klin Chem"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB5","first-page":"172","article-title":"Hypereosinophilic syndrome with pulmonary and cardiac involvement in a patient with asthma","volume":"168","author":"Karnak","year":"2003","journal-title":"CMAJ"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB6","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V93.5.1651","article-title":"Clonality of isolated eosinophils in the hypereosinophilic syndrome","volume":"93","author":"Chang","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB8","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2141.2000.02097.x","article-title":"Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome","volume":"109","author":"Roufosse","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB11","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1086\/302053","article-title":"Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33","volume":"63","author":"Rioux","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev.med.54.101601.152431","article-title":"The hypereosinophilic syndrome revisited","volume":"54","author":"Roufosse","year":"2003","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-89-2-167","article-title":"Therapy of the hypereosinophilic syndrome","volume":"89","author":"Parrillo","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ajh.2830450311","article-title":"Alpha-interferon treatment for idiopathic hypereosinophilic syndrome","volume":"45","author":"Bockenstedt","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1542\/peds.99.4.630","article-title":"Treatment of hypereosinophilic syndrome in a child using cyclosporine","volume":"99","author":"Nadarajah","year":"1997","journal-title":"Pediatrics"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/BF01729838","article-title":"Cyclosporin for hypereosinophilic syndrome","volume":"62","author":"Zabel","year":"1991","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB17","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/sj.leu.2400717","article-title":"2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome","volume":"11","author":"Ueno","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2141.1995.tb03404.x","article-title":"Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome","volume":"90","author":"Fukushima","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bmt.1702102","article-title":"Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis","volume":"25","author":"Vazquez","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB21","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB25","first-page":"9","article-title":"Case report","volume":"3","author":"Schaller","year":"2001","journal-title":"MedGenMed"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB27","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB28","first-page":"798a","article-title":"Imatinib mesylate (GLEEVEC) induces rapid and complex hematologic remissions in patients with idiopathic hypereosinophilic syndrome (HES) without evidence of BCR-ABL or activating mutations in C-KIT and platelet-derived growth factor receptor-beta (PDGFR-\u03b2)","volume":"100","author":"Gotlib","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB30","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB31","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB33","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB34","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2004.03.035_BIB36","first-page":"563","article-title":"Oral PKC 412 has activity in patients (pts) with mutant FLT3 acute myeloid leukemia (AML)","volume":"22","author":"Stone","year":"2003","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404001514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404001514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:02:30Z","timestamp":1586523750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404001514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":36,"alternative-id":["S0093775404001514"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.03.035","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}